A Single Arm Phase II Trial of BMN 673 for Inoperable, Advanced Endometrial Cancer With Retrospective PTEN, MSI and MRE11 Analysis

Next Previous
Trial Profile

A Single Arm Phase II Trial of BMN 673 for Inoperable, Advanced Endometrial Cancer With Retrospective PTEN, MSI and MRE11 Analysis

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Talazoparib (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Acronyms PANDA

    • Most Recent Events

    • 16 Dec 2015 Status changed from not yet recruiting to withdrawn prior to enrolment, according to United Kingdom Clinical Research Network record.
    • 14 Dec 2015 Planned primary completion date changed from 1 Dec 2017 to 1 Oct 2018 as reported by ClinicalTrials.gov record.
    • 21 Jul 2015 UKCRN reports closure date as 30 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top